[Analysis of Genetic Characteristics and Clinical Efficacy in Pediatric Acute Myeloid Leukemia with NUP98∷KDM5A Fusion Gene Positive].
To explore the genetic characteristics and clinical efficacy of pediatric acute myeloid leukemia (AML) with NUP98∷KDM5A fusion gene positive.
The laboratory and clinical characteristics of 10 NUP98∷KDM5A-positive pediatric AML patients identified by transcriptome sequencing (RNA-seq) were retrospectively analyzed during the period from March 2018 to March 2024 at Hebei Yanda Ludaopei Hospital and Beijing Ludaopei Hospital. Survival curves were plotted using the Kaplan-Meier method, and the 1-year overall survival and cumulative recurrence rates were calculated.
The median onset age of the 10 patients was 2(1-4) years, with a male to female ratio of 3∶7. All patients presented with thrombocytopenia, skin ecchymosis, and/or scattered petechiae as the main clinical manifestations. According to the FAB classification, 7 cases were diagnosed as AML-M7, 2 as AML-M5, and 1 as AML-M2. Cytogenetic analysis showed that 8 pediatric patients exhibited structural abnormalities involving chromosome 13 at initial diagnosis, relapse, or post-transplant relapse, and mainly manifested as del(13q). RNA-seq results showed that 9 patients had a fusion of NUP98 exon 13 with KDM5A exon 27, and 1 patient had a fusion of NUP98 exon 13 with KDM5A exon 25. Expression levels of MECOM and PRDM16 genes in the patient group were significantly higher than in the normal control group (P <0.05). Among co-occurring genetic mutations, JAK2 gene mutations exhibited the highest frequency of occurrence (40%). All patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), with 7 in complete remission (CR) and 3 in partial remission (PR)/non-remission (NR) before transplantation. The median follow-up time was 5.8 (2.5-23.7) months. During the follow-up period, 3 patients survived and 7 died, among which 6 died from relapse and 1 died from acute graft-versus-host disease of the gut post-transplantation. The median survival time post-transplantation was 7.8 months (95%CI : 0.8-14.8 months), the median relapse time was 5.5 months (95%CI : 0-11.7 months), the 1-year overall survival rate was 34.3%, and cumulative relapse rate was 55%.
Pediatric AML with the NUP98∷KDM5A fusion gene is more common in the M7 subtype, predominantly in females, and is often associated with chromosome 13 abnormalities and a higher rate of JAK2 mutations. Allo-HSCT can partially improve the prognosis of pediatric AML positive for NUP98∷KDM5A, but the relapse rate is high, and relapse is a significant factor affecting patient survival.
The laboratory and clinical characteristics of 10 NUP98∷KDM5A-positive pediatric AML patients identified by transcriptome sequencing (RNA-seq) were retrospectively analyzed during the period from March 2018 to March 2024 at Hebei Yanda Ludaopei Hospital and Beijing Ludaopei Hospital. Survival curves were plotted using the Kaplan-Meier method, and the 1-year overall survival and cumulative recurrence rates were calculated.
The median onset age of the 10 patients was 2(1-4) years, with a male to female ratio of 3∶7. All patients presented with thrombocytopenia, skin ecchymosis, and/or scattered petechiae as the main clinical manifestations. According to the FAB classification, 7 cases were diagnosed as AML-M7, 2 as AML-M5, and 1 as AML-M2. Cytogenetic analysis showed that 8 pediatric patients exhibited structural abnormalities involving chromosome 13 at initial diagnosis, relapse, or post-transplant relapse, and mainly manifested as del(13q). RNA-seq results showed that 9 patients had a fusion of NUP98 exon 13 with KDM5A exon 27, and 1 patient had a fusion of NUP98 exon 13 with KDM5A exon 25. Expression levels of MECOM and PRDM16 genes in the patient group were significantly higher than in the normal control group (P <0.05). Among co-occurring genetic mutations, JAK2 gene mutations exhibited the highest frequency of occurrence (40%). All patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), with 7 in complete remission (CR) and 3 in partial remission (PR)/non-remission (NR) before transplantation. The median follow-up time was 5.8 (2.5-23.7) months. During the follow-up period, 3 patients survived and 7 died, among which 6 died from relapse and 1 died from acute graft-versus-host disease of the gut post-transplantation. The median survival time post-transplantation was 7.8 months (95%CI : 0.8-14.8 months), the median relapse time was 5.5 months (95%CI : 0-11.7 months), the 1-year overall survival rate was 34.3%, and cumulative relapse rate was 55%.
Pediatric AML with the NUP98∷KDM5A fusion gene is more common in the M7 subtype, predominantly in females, and is often associated with chromosome 13 abnormalities and a higher rate of JAK2 mutations. Allo-HSCT can partially improve the prognosis of pediatric AML positive for NUP98∷KDM5A, but the relapse rate is high, and relapse is a significant factor affecting patient survival.
Authors
Li Li, Chen Chen, Long Long, Fang Fang, Ma Ma, Yuan Yuan, Yin Yin, Pan Pan, Su Su, Sun Sun, Wang Wang, Wang Wang
View on Pubmed